StockData
BioCryst Pharmaceuticals Inc logo

BioCryst Pharmaceuticals Inc (BCRX) stock

BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$7.50+0.05 (+0.67%)

Close on Nov 17, 2026Market cap $1.92BP/E –Yield –

BioCryst Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

BioCryst Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was $376.14M, up 2136.6% year over year. For fiscal 2025 it was $347.37M. The highest annual figure on record is $347.37M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$347.37M–
FY2024Dec 31, 2024-$52.02M–
FY2023Dec 31, 2023-$95.14M–
FY2022Dec 31, 2022-$161.85M–
FY2021Dec 31, 2021-$142.16M–
FY2020Dec 31, 2020-$135.11M–
FY2019Dec 31, 2019-$89.58M–
FY2018Dec 31, 2018-$92.57M–
FY2017Dec 31, 2017-$41.14M–
FY2016Dec 31, 2016-$53.44M–
FY2015Dec 31, 2015-$13.12M–
FY2014Dec 31, 2014-$38.55M–
FY2013Dec 31, 2013-$26.53M–
FY2012Dec 31, 2012-$37.40M–
FY2011Dec 31, 2011-$32.25M–
FY2010Dec 31, 2010-$28.56M–
FY2009Dec 31, 2009-$16.22M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$104.34M+152.6%
Q1 FY2026Mar 31, 2026-$61.79M–
Q4 FY2025Dec 31, 2025$291.96M–
Q3 FY2025Sep 30, 2025$41.62M+404.8%
Q2 FY2025Jun 30, 2025$41.30M–
Q1 FY2025Mar 31, 2025-$27.52M–
Q4 FY2024Dec 31, 2024-$5.21M–
Q3 FY2024Sep 30, 2024$8.25M–
Q2 FY2024Jun 30, 2024-$1.37M–
Q1 FY2024Mar 31, 2024-$53.68M–
Q4 FY2023Dec 31, 2023-$8.92M–
Q3 FY2023Sep 30, 2023-$19.90M–
Q2 FY2023Jun 30, 2023-$18.81M–
Q1 FY2023Mar 31, 2023-$47.51M–
Q4 FY2022Dec 31, 2022-$23.85M–
Q3 FY2022Sep 30, 2022-$32.44M–
Q2 FY2022Jun 30, 2022-$27.76M–
Q1 FY2022Mar 31, 2022-$77.80M–
Q4 FY2021Dec 31, 2021-$32.46M–
Q3 FY2021Sep 30, 2021-$23.28M–
Q2 FY2021Jun 30, 2021-$25.41M–
Q1 FY2021Mar 31, 2021-$61.01M–
Q4 FY2020Dec 31, 2020-$42.53M–
Q3 FY2020Sep 30, 2020-$38.26M–
Q2 FY2020Jun 30, 2020-$31.04M–
Q1 FY2020Mar 31, 2020-$23.28M–
Q4 FY2019Dec 31, 2019-$10.45M–
Q3 FY2019Sep 30, 2019-$27.64M–
Q2 FY2019Jun 30, 2019-$24.50M–
Q1 FY2019Mar 31, 2019-$27.00M–
Q4 FY2018Dec 31, 2018-$23.99M–
Q3 FY2018Sep 30, 2018-$35.03M–
Q2 FY2018Jun 30, 2018-$13.90M–
Q1 FY2018Mar 31, 2018-$19.65M–
Q4 FY2017Dec 31, 2017-$10.52M–
Q3 FY2017Sep 30, 2017-$12.43M–
Q2 FY2017Jun 30, 2017-$9.67M–
Q1 FY2017Mar 31, 2017-$8.53M–
Q4 FY2016Dec 31, 2016-$5.85M–
Q3 FY2016Sep 30, 2016-$17.56M–

More BioCryst Pharmaceuticals figures

See a number that looks wrong?